BC Innovations | Nov 13, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis Mouse studies suggest inhibiting MCP-1 or its receptor CCR2 could help treat arthritis. In a mouse model of anti-collagen antibody-induced arthritis, systemic MCP-1 knockout or a neutralizing antibody against CCR2 decreased disease severity...
BC Innovations | Oct 11, 2018
Distillery Therapeutics

Ophthalmic disease

INDICATION: Retinal detachment Mouse studies suggest inhibiting TRPV4 or its downstream mediator MCP-1 could help treat retinal detachment. In a mouse model of retinal detachment, systemic or Müller glia- and astrocyte-specific TRPV4 knockout, a tool...
BC Innovations | Sep 10, 2018
Distillery Therapeutics

Neurology

INDICATION: Encephalopathy Patient sample and mouse studies suggest inhibiting the JAK/STAT1 pathway, the interaction between MCP-1 and CCR2, or phagocyte activation could help treat Rasmussen encephalitis. In postmortem brain samples from patients, levels of phosphorylated...
BC Innovations | Nov 15, 2017
Distillery Therapeutics

Ophthalmic disease

INDICATION: Retinopathy of prematurity Patient sample and mouse studies suggest inhibiting mast cell degranulation, TPSB2 or MCP-1-CCR2 signaling could help treat retinopathy of prematurity (ROP). In plasma samples from preterm neonatal infants who developed ROP,...
BC Innovations | May 31, 2017
Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary Patient sample and mouse studies suggest inhibiting KRAS or MCP-1 could help treat malignant pleural effusions in KRAS-mutant cancers. In non-small cell lung cancer (NSCLC) patients, KRAS mutations in metastatic tumors were associated...
BC Innovations | Mar 21, 2017
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample and mouse studies suggest inhibiting MCP-1 could help treat glioblastoma multiforme (GBM). In patients, high tumor levels of MCP-1 were associated with poor survival. In a mouse model of GBM,...
BC Innovations | Oct 13, 2016
Distillery Therapeutics

Therapeutics: Monocyte chemoattractant protein-1 (MCP-1; CCL2)

Cardiovascular disease INDICATION: Atherosclerosis Mouse studies suggest inhibiting MCP-1 in bone marrow stromal cells could help treat atherosclerosis. In a mouse model of atherosclerosis, MCP-1 knockout in cells expressing nestin (NES) - a marker for bone...
BC Week In Review | Apr 7, 2014
Clinical News

Emapticap pegol: Phase IIa data

A double-blind, international Phase IIa trial in 75 Type II diabetics with albuminuria on current standard of care to control hypertension, hyperglycemia and dyslipidemia showed that twice-weekly 0.5 mg/kg subcutaneous NOX-E36 met the primary endpoint...
BC Extra | Apr 5, 2014
Clinical News

Noxxon's NOX-E36 meets in diabetic nephropathy trial

Noxxon Pharma AG (Berlin, Germany) said twice-weekly subcutaneous NOX-E36 met the primary endpoint vs. placebo in a Phase IIa trial to treat diabetic nephropathy. NOX-E36 reduced urinary albumin excretion as measured by the change from...
BC Week In Review | Aug 5, 2013
Clinical News

NOX-E36: Completed Phase IIa enrollment

Noxxon completed enrollment of 75 Type II diabetics with albuminuria in a double-blind, placebo-controlled, German Phase IIa trial evaluating 0.5 mg/kg subcutaneous NOX-E36 twice weekly for 12 weeks. All patients will receive standard of care...
Items per page:
1 - 10 of 20